EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.2 · CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Preferred shares | Amount | Common shares | Amount | Additional paid-in capital | Deficit | Accumulated other comprehensive loss | Non- controlling interest | Total-Shareholders’Equity | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2022 | — | — | 21,593,145 | 71,003,225 | 16,850,165 | (77,280,499) | (2,786,366) | (578,671) | 7,207,854 |
| Non-brokered private placement, net of transaction costs (Note 12(b)(iii)) | — | — | 3,282,936 | 15,886,537 | — | — | — | — | 15,886,537 |
| Share-based payments (Note 12(d)) | — | — | — | — | 1,412,257 | — | — | — | 1,412,257 |
| Redemption of warrants (Notes 12(b)(i) and 12(e)) | — | — | 2,385,484 | 5,974,988 | (733,177) | — | — | — | 5,241,811 |
| Redemption of options (Notes 12(b)(ii) and 12(d)) | — | — | 20,600 | 48,835 | (18,776) | — | — | — | 30,059 |
| Net loss for the year | — | — | — | — | — | (28,220,796) | — | (745,210) | (28,966,006) |
| Foreign currency translation adjustment | — | — | — | — | — | — | 79,814 | — | 79,814 |
| Balance, December 31, 2023 | — | $— | 27,282,165 | $92,913,585 | $17,510,469 | $(105,501,295) | $(2,706,552) | $(1,323,881) | $892,326 |
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Preferred shares | Amount | Common shares | Amount | Additional paid-in capital | Deficit | Accumulated other comprehensive loss | Non- controlling interest | Total-ShareholdersEquity | |
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | — | — | 27,282,165 | $92,913,585 | $17,510,469 | $(105,501,295) | $(2,706,552) | $(1,323,881) | $892,326 |
| Overnight marketed offering, net of transaction costs (Note 12(b)(vi)) | — | — | 8,260,435 | 22,853,391 | — | — | — | — | 22,853,391 |
| Non-brokered private placement, net of transaction costs (Note 12(c)) | 8,905,638 | 31,705,219 | — | — | — | — | — | — | 31,705,219 |
| Share-based payments (Note 12(d)) | — | — | — | — | 3,223,464 | — | — | — | 3,223,464 |
| Redemption of warrants (Notes 12(b)(iv) and 12(e)) | — | — | 80,243 | 551,941 | (214,125) | — | — | — | 337,816 |
| Redemption of options (Notes 12(b)(v) and 12(d)) | — | — | 18,760 | 41,149 | (15,904) | — | — | — | 25,245 |
| Net loss for the year | — | — | — | — | — | (25,502,536) | — | (241,953) | (25,744,489) |
| Foreign currency translation adjustment | — | — | — | — | — | — | (1,454,003) | — | (1,454,003) |
| Balance, December 31, 2024 | 8,905,638 | $31,705,219 | 35,641,603 | $116,360,066 | $20,503,904 | $(131,003,831) | $(4,160,555) | $(1,565,834) | $31,838,969 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.